Article Details

PDS0101 Plus Pembrolizumab Elicits 74% 2-Year OS Rate in ICI-Naïve, HPV16+ HNSCC

Retrieved on: 2023-10-03 16:37:33

Tags for this article:

Click the tags to see associated articles and topics

PDS0101 Plus Pembrolizumab Elicits 74% 2-Year OS Rate in ICI-Naïve, HPV16+ HNSCC. View article details on HISWAI: https://www.onclive.com/view/pds0101-plus-pembrolizumab-elicits-74-2-year-os-rate-in-ici-na-ve-hpv16-hnscc

Excerpt

Aside from understanding the immune cells in the tumor microenvironment, it is also important to be aware of the immune response in the patient ...

Article found on: www.onclive.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up